Stockscreener 앱 받기
12.33
3.75%
-0.4772
전일 마감가:
$12.81
열려 있는:
$12.8
하루 거래량:
1.11M
Relative Volume:
0.71
시가총액:
$1.38B
수익:
$577.74M
순이익/손실:
$-149.78M
주가수익비율:
-8.8091
EPS:
-1.4
순현금흐름:
$-78.21M
1주 성능:
-9.20%
1개월 성능:
-15.89%
6개월 성능:
-32.07%
1년 성능:
-23.79%
1일 변동 폭
$12.19
$12.80
1주일 범위
$12.19
$14.22
52주 변동 폭
$10.87
$34.13
Novocure Ltd Stock (NVCR) Company Profile
명칭
Novocure Ltd
전화
44 (0)15 3475 6700
주소
NO. 4 THE FORUM, ST. HELIER
NVCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
12.34 | 1.43B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
123.83 | 214.96B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.95 | 149.24B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
359.49 | 136.23B | 24.38B | 2.94B | 4.02B | 7.6145 |
|
MDT
Medtronic Plc
|
89.81 | 116.33B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.01 | 48.41B | 5.88B | 1.34B | 577.90M | 2.3455 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-12-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-10-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 개시 | SVB Securities | Outperform |
| 2023-07-31 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2023-06-07 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2023-05-16 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 재확인 | H.C. Wainwright | Buy |
| 2022-11-29 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 개시 | H.C. Wainwright | Buy |
| 2022-02-08 | 개시 | Loop Capital | Buy |
| 2022-02-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2022-01-03 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-07-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-14 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-01-25 | 재확인 | Piper Sandler | Overweight |
| 2020-09-23 | 개시 | Northland Capital | Outperform |
| 2020-09-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | 다운그레이드 | Truist | Buy → Hold |
| 2020-06-01 | 재개 | Oppenheimer | Perform |
| 2020-05-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-04-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2020-03-05 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-29 | 업그레이드 | SunTrust | Hold → Buy |
| 2019-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-07-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2018-11-02 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 개시 | Evercore ISI | Outperform |
| 2018-04-18 | 재확인 | Mizuho | Buy |
| 2018-02-23 | 재확인 | Mizuho | Buy |
| 2017-05-24 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 재확인 | Wedbush | Outperform |
| 2016-01-19 | 개시 | Barclays | Underweight |
| 2015-12-02 | 개시 | Deutsche Bank | Hold |
모두보기
Novocure Ltd 주식(NVCR)의 최신 뉴스
NovoCure (NVCR) Is Down 5.7% After Q3 Revenue Growth and Expanded International Coverage — Has the Growth Story Changed? - simplywall.st
HC Wainwright Increases Earnings Estimates for NovoCure - MarketBeat
Chart overlay techniques for tracking NovoCure LimitedQuarterly Trade Summary & Free Safe Entry Trade Signal Reports - newser.com
Is NovoCure Limited stock attractive for hedge fundsGDP Growth & Pattern Based Trade Signal System - newser.com
Is NovoCure Limited stock oversold or undervaluedGap Up & Weekly Momentum Stock Picks - newser.com
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Q3 2025 Earnings Call Transcript - Insider Monkey
How interest rate cuts could boost NovoCure Limited stockJuly 2025 Opening Moves & Verified Chart Pattern Signals - newser.com
What does recent volatility data suggest for NovoCure LimitedJuly 2025 Reactions & Consistent Profit Trade Alerts - newser.com
NovoCure’s Mixed Q3: Growth Amid Challenges - TipRanks
NovoCure (NVCR): Losses Worsen, Testing Bullish Narrative on Valuation and Growth Potential - simplywall.st
NovoCure (NASDAQ:NVCR) Announces Quarterly Earnings Results - MarketBeat
NovoCure (NASDAQ:NVCR) Price Target Raised to $42.00 - MarketBeat
NovoCure: Q3 Earnings Snapshot - Stamford Advocate
Novocure Ltd earnings beat by $0.09, revenue topped estimates - Investing.com UK
Emerald Mutual Fund Advisers Trust Reduces Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Expands Global Reach Within Nasdaq Today Trends - Kalkine Media
Novocure Ltd. Reports Q3 2025 Financial Results - TipRanks
Order flow analysis tools used on NovoCure Limited2025 Top Decliners & AI Driven Price Predictions - newser.com
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
HC Wainwright & Co. Raises PT for NVCR, Maintains Buy Rating | N - GuruFocus
Assessing NovoCure (NVCR) Valuation as Investors Revisit Recovery Potential - simplywall.st
NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges - Yahoo Finance
Novocure’s Revenue Beats Forecasts As Cancer Pipeline Expands - Finimize
Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Novocure (NVCR) Exceeds Q3 Revenue Expectations with Strong Grow - GuruFocus
Emerald Advisers LLC Lowers Stock Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Ltd (NVCR) Q3 Earnings: EPS Loss of $0.33 Beats Estimat - GuruFocus
Novocure (NASDAQ: NVCR) posts $167.2M revenue for the quarter; 4,416 patients on therapy - Stock Titan
Can NovoCure Limited hit a new high this monthJuly 2025 Chart Watch & Safe Entry Point Identification - newser.com
Measuring NovoCure Limited’s beta against major indices2025 Earnings Surprises & Verified High Yield Trade Plans - newser.com
NovoCure (NASDAQ:NVCR) Given New $23.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Real time breakdown of NovoCure Limited stock performanceWeekly Risk Summary & Weekly Setup with High ROI Potential - newser.com
Is NovoCure Limited stock a safe investment in uncertain marketsJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Why NovoCure Limited stock remains undervaluedQuarterly Earnings Report & High Accuracy Trade Alerts - newser.com
Will NovoCure Limited stock attract more institutional investorsQuarterly Risk Review & Accurate Entry and Exit Point Alerts - newser.com
Detecting support and resistance levels for NovoCure LimitedJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Is NovoCure Limited (038) stock testing key supportJuly 2025 Sector Moves & Real-Time Market Sentiment Alerts - newser.com
NovoCure’s Phase 3 Glioblastoma Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Will NovoCure Limited (038) stock profit from automation waveMarket Movement Recap & Expert Verified Stock Movement Alerts - fcp.pa.gov.br
JP Morgan Maintains NovoCure (NVCR) Neutral Recommendation - Nasdaq
NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment - TipRanks
Will NovoCure Limited stock outperform growth indexes2025 Top Decliners & Low Risk Entry Point Guides - fcp.pa.gov.br
NovoCure’s TIGER Meso Study: A Promising Update for Pleural Mesothelioma Treatment - TipRanks
NovoCure’s LUNAR-4 Study: A New Horizon in Lung Cancer Treatment - TipRanks
How strong is NovoCure Limited stock revenue growthTrade Exit Summary & Entry Point Strategy Guides - fcp.pa.gov.br
NovoCure’s TIGER France Study: A Potential Game-Changer for Glioblastoma Treatment - TipRanks
JP Morgan Maintains Neutral Rating on NVCR, Lowers Price Target - GuruFocus
What sentiment indicators say about NovoCure Limited stock2025 Price Momentum & Reliable Trade Execution Plans - newser.com
How NovoCure Limited (038) stock responds to job market shiftsJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - newser.com
Forecasting NovoCure Limited price range with options dataWall Street Watch & Free Community Supported Trade Ideas - newser.com
Novocure Ltd (NVCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Novocure Ltd 주식 (NVCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Brackmann Christoph | Chief Financial Officer |
Jul 29 '25 |
Buy |
11.59 |
20,000 |
231,800 |
141,150 |
| Stafford Kristin | Director |
Jun 03 '25 |
Sale |
17.28 |
999 |
17,259 |
3,054 |
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
2.29%
1.48%
자본화:
|
볼륨(24시간):